×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NDRA – endra life sciences inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NDRA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/22
08:11 am
ndra
ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement [Yahoo! Finance]
Medium
Report
ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement [Yahoo! Finance]
11/22
08:00 am
ndra
ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Low
Report
ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
11/15
09:32 am
ndra
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update [Yahoo! Finance]
High
Report
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update [Yahoo! Finance]
11/15
09:24 am
ndra
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
High
Report
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
11/12
08:00 am
ndra
Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024
Low
Report
Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024
11/6
08:00 am
ndra
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent
High
Report
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent
10/22
08:00 am
ndra
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany
High
Report
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany
8/28
04:23 pm
ndra
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements [Yahoo! Finance]
High
Report
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/22
08:43 am
ndra
Form 8-K ENDRA Life Sciences Inc. For: Nov 22
Low
Report
Form 8-K ENDRA Life Sciences Inc. For: Nov 22
11/21
05:15 pm
ndra
Form 10-Q/A ENDRA Life Sciences Inc. For: Sep 30
Low
Report
Form 10-Q/A ENDRA Life Sciences Inc. For: Sep 30
11/19
05:14 pm
ndra
Form 10-Q ENDRA Life Sciences Inc. For: Sep 30
Medium
Report
Form 10-Q ENDRA Life Sciences Inc. For: Sep 30
11/15
04:07 pm
ndra
Form 8-K ENDRA Life Sciences Inc. For: Nov 15
High
Report
Form 8-K ENDRA Life Sciences Inc. For: Nov 15
11/15
04:02 pm
ndra
Form NT 10-Q ENDRA Life Sciences Inc. For: Sep 30
High
Report
Form NT 10-Q ENDRA Life Sciences Inc. For: Sep 30
11/5
08:01 am
ndra
Form 8-K ENDRA Life Sciences Inc. For: Nov 04
Low
Report
Form 8-K ENDRA Life Sciences Inc. For: Nov 04
10/29
04:05 pm
ndra
Form 8-K ENDRA Life Sciences Inc. For: Oct 28
High
Report
Form 8-K ENDRA Life Sciences Inc. For: Oct 28
9/17
06:01 am
ndra
Form DEFA14A ENDRA Life Sciences Inc.
Low
Report
Form DEFA14A ENDRA Life Sciences Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/19
ENDRA Life Sciences Submits Technical File for CE Mark
30.7%
6/13 ENDRA Life Sciences Inc (NASDAQ: NDRA) is now covered by analysts at Dougherty & Co. They set a "buy" rating on the stock. 25.9%
4/13 Form 4 ENDRA Life Sciences Inc. For: Apr 09 Filed by: Gambhir Sanjiv Sam 18.3%
12/11 Form 4 ENDRA Life Sciences Inc. For: Dec 11 Filed by: Gambhir Sanjiv Sam 16.7%
10/17 ENDRA Life Sciences Inc (NASDAQ: NDRA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 13.2%
12/27 Form 8-K ENDRA Life Sciences Inc. For: Dec 27 13.0%
11/14 ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.0%
3/19 ENDRA Life Sciences Provides Update on FDA Regulatory Timeline 8.8%
5/20 Form 4 ENDRA Life Sciences Inc. For: May 16 Filed by: Thornton Michael Milos 7.9%
7/29 ENDRA Life Sciences Completes Private Placement of $2.8 Million of Convertible Secured Notes and Warrants 6.5%
6/13 ENDRA Life Sciences Inc (NASDAQ: NDRA) is now covered by analysts at Dougherty & Co. They set a "buy" rating on the stock. 25.9%
4/13 Form 4 ENDRA Life Sciences Inc. For: Apr 09 Filed by: Gambhir Sanjiv Sam 18.3%
12/11 Form 4 ENDRA Life Sciences Inc. For: Dec 11 Filed by: Gambhir Sanjiv Sam 16.7%
10/17 ENDRA Life Sciences Inc (NASDAQ: NDRA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 13.2%
12/27 Form 8-K ENDRA Life Sciences Inc. For: Dec 27 13.0%
11/14 ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.0%
3/19 ENDRA Life Sciences Provides Update on FDA Regulatory Timeline 8.8%
5/20 Form 4 ENDRA Life Sciences Inc. For: May 16 Filed by: Thornton Michael Milos 7.9%
7/29 ENDRA Life Sciences Completes Private Placement of $2.8 Million of Convertible Secured Notes and Warrants 6.5%
TOP News Decliners
3/27
Form 424B5 ENDRA Life Sciences Inc.
-22.4%
5/14 Form 10-Q ENDRA Life Sciences Inc. For: Mar 31 -22.0%
3/26 Form 8-K ENDRA Life Sciences Inc. For: Mar 26 -19.1%
11/19 ENDRA Life Sciences Inc (NASDAQ: NDRA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -16.1%
1/28 Form 424B3 ENDRA Life Sciences Inc. -13.8%
4/3 Form 8-K ENDRA Life Sciences Inc. For: Mar 31 -12.8%
1/15 Form 8-K ENDRA Life Sciences Inc. For: Jan 13 -12.6%
10/14 ENDRA Life Sciences to present at H.C. Wainwright 3rd Annual NASH Investor Conference -12.6%
11/18 ENDRA Life Sciences Inc (NASDAQ: NDRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. -11.2%
1/10 Form S-3 ENDRA Life Sciences Inc. -11.1%
5/14 Form 10-Q ENDRA Life Sciences Inc. For: Mar 31 -22.0%
3/26 Form 8-K ENDRA Life Sciences Inc. For: Mar 26 -19.1%
11/19 ENDRA Life Sciences Inc (NASDAQ: NDRA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -16.1%
1/28 Form 424B3 ENDRA Life Sciences Inc. -13.8%
4/3 Form 8-K ENDRA Life Sciences Inc. For: Mar 31 -12.8%
1/15 Form 8-K ENDRA Life Sciences Inc. For: Jan 13 -12.6%
10/14 ENDRA Life Sciences to present at H.C. Wainwright 3rd Annual NASH Investor Conference -12.6%
11/18 ENDRA Life Sciences Inc (NASDAQ: NDRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. -11.2%
1/10 Form S-3 ENDRA Life Sciences Inc. -11.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: